High interstitial fluid pressure — an obstacle in cancer therapy

By C. Heldin, K. Rubin, K. Pietras, A. Ostman. Nature Reviews. Cancer, 2004

2,171 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/6635fa7b37888f0f90c64afdfcb8ca09d3ae974f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. (2012, background): “Although the function of the newly formed lymphatics was not tested, i.e., whether the skin lymph flow was actually increased, they concluded that TonEBP-VEGF-C signaling in macrophages were major determinants of extracellular fluid volume and blood pressure.”
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, background): “(ii) As previously mentioned, the high interstitial fluid pressure of solid tumors avoids successful uptake and homogenous distribution of drugs in the tumor [24].”
Integrin-mediated mechanotransduction (2016, background): “In pancreatic ductal adenocarcinoma, which is known for its insensitivity to chemotherapy and immunotherapy, ∼90% of the tumor mass is composed of a thick desmoplastic stroma that maintains an immunosuppressive tumor microenvironment and impedes drug delivery (Heldin et al., 2004; Olive et al., 2009”
Therapeutic targeting of the tumor microenvironment. (2005, positive): “One of these barriers is an increase in IFP within tumors (particularly at the tumor core) that is significantly higher than in normal tissues (reviewed in Heldin et al., 2004).”
Tumor angiogenesis and vascular normalization: alternative therapeutic targets (2017, background): “Interestingly, the remaining uncompressed vessels often display excessive blood flow, which contributes to the increased IFP in tumors [46].”
In search of definitions: Cancer‐associated fibroblasts and their markers (2019, background): “types of cells and factors have been described to play a role in the TME, ranging from immune cells, such as T, B and natural killer (NK) cells,(2) to wider environmental factors, such as extracellular matrix (ECM) stiffness,(3) hypoxia(4) and interstitial pressure.(5) Amongst all these various micr”
Dynamic interplay between the collagen scaffold and tumor evolution (2010, background): “The increased interstitial fluid pressure is due in part to a leaky vasculature and sparse or nonfunctional lymphatics [72].”
Drug penetration in solid tumours (2006, neutral): “causes increased interstitial fluid pressure (IFP”
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. (2013, background): “[86] demonstrated that the addition of low-dose tumor necrosis factor-α (TNF-α), which is a proinflammatory cytokine with known vascular permeabilising activity, to systemic injections with PEGylated liposomes augmented tumor accumulation of these liposomes by 5- to 6fold, which strongly correlated ”
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. (2012, background): “These include the presence of pericyte-, smooth muscle cell- and fibroblast-based cell layers between endothelial and tumor cells, the high cellular density within solid malignancies, and the high interstitial fluid pressure that is typical of tumors [11,19].”
Matrix as an Interstitial Transport System (2014, background): “One more function of the ECM is regulating the interstitial hydrostatic pressure and subsequently the transcapillary exchange,(192) which are also affected by the concentration of soluble molecules (eg, cytokines, growth factor, and angiogenic factors) in the interstitial fluid phase.(193,194) This ”